Treatment with cyclosporine A 0.1% can reduce ocular surface temperature in patients with dry eye disease and meibomian gland dysfunction.

For patients with microbial keratitis (MK), initial vision, longer time to presentation, and larger stromal infiltrate size lead to a higher risk for worse 90-day best-corrected visual acuity (BCVA).